Fangsheng Pharmaceutical announced that as of September 30, 2025, the company's net profit attributable to shareholders of listed companies for the first three quarters of 2025 was 268 million yuan. According to the resolution of the board of directors, the company plans to distribute profits based on the total share capital registered on the share registration date for implementing equity distribution in 2025. The profit distribution plan is as follows: The listed company plans to distribute a cash dividend of 0.15 yuan per share to all shareholders. As of September 30, 2025, the total share capital of the company was 439 million shares. Based on this calculation, the total proposed cash dividend was 658.622 million yuan, accounting for 24.55% of the company's net profit attributable to shareholders of listed companies in the first three quarters of 2025.

Fangsheng Pharmaceutical announced that as of September 30, 2025, the company's net profit attributable to shareholders of listed companies for the first three quarters of 2025 was 268 million yuan. According to the resolution of the board of directors, the company plans to distribute profits based on the total share capital registered on the share registration date for implementing equity distribution in 2025. The profit distribution plan is as follows: The listed company plans to distribute a cash dividend of 0.15 yuan per share to all shareholders. As of September 30, 2025, the total share capital of the company was 439 million shares. Based on this calculation, the total proposed cash dividend was 658.622 million yuan, accounting for 24.55% of the company's net profit attributable to shareholders of listed companies in the first three quarters of 2025.